Source comparison
Half-Life Comparison: Duration Dictates Dosing Frequency and Receptor Exposure
Half-life is the single most important pharmacokinetic parameter when choosing between CJC-1295 and other research peptides. CJC-1295 with DAC has a terminal half-life of approximately 6–8 days, meaning plasma concentrations decline by 50% every six days. In r
This comparison does not assign a generated winner or score.
- Half-life is the single most important pharmacokinetic parameter when choosing between CJC-1295 and other research peptides. CJC-1295 with DAC has a terminal half-life of approximately 6–8 days, meaning plasma concentrations decline by 50% every six days. In research models, this translates to once-weekly dosing. CJC-1295 without DAC (often called Modified GRF 1-29) lacks the albumin-binding modification and has a half-life of approximately 30 minutes. Functionally identical to GHRP compounds.
- For comparison: GHRP-2 and ipamorelin both exhibit half-lives under 2 hours. Hexarelin, another potent ghrelin receptor agonist, clears even faster at approximately 70 minutes. MK-677 (ibutamoren), an oral ghrelin mimetic, extends duration to 24 hours but still requires daily dosing and produces continuous GH elevation rather than pulsatile release.
- The practical implication: multi-day experiments with CJC-1295 require one subcutaneous administration per week, while equivalent protocols using GHRP-2 demand 2–3 daily injections to sustain elevated GH. Cognitive peptides like Semax or Selank operate on entirely different timelines. Semax has a half-life under 10 minutes but exerts neuroplastic effects persisting hours beyond clearance, while Selank's anxiolytic properties emerge after 5–7 days of repeated dosing despite rapid plasma elimination.